Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

FDA Expert Panel to Review Merck's New HIV Treatment Isentress in September

From U.S. Centers for Disease Control and Prevention

July 12, 2007

On Sept. 5, the Food and Drug Administration's antiviral panel will meet to assess the safety and efficacy of Isentress, a new HIV drug from Merck & Co. The drug's target market is patients who no longer respond to at least one drug in three antiviral classes. FDA last month granted priority review status to Isentress, a designation that acknowledges the candidate drug fills an urgent medical need and that reduces, from 10 months to six, the length of the review period. Merck said its trials show Isentress effectively reduced HIV viral load in more than 75 percent of study patients. FDA typically follows the advice of its expert panels; a final decision is anticipated by mid-October.

Back to other news for July 2007

Adapted from:
Associated Press
07.11.2007


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement